In China, chronic obstructive pulmonary disease (COPD) is a prevalent chronic disorder. With high incidence and mortality, it burdens both individual health and socioeconomic systems. Pharmacological treatment is essential for COPD management, and personalized therapy is key. Triple therapy combining inhaled corticosteroids (ICS), long-acting muscarinic antagonist (LAMA), and long-acting beta-agonist (LABA) has become a focal point. In 2024 Italy has refined the management of COPD patients through the establishment of an expert panel focusing on the applicability of triple therapy in order to standardize the management of patients with COPD and published the "An Italian Delphi Consensus on the Triple Inhalation Therapy in Chronic Obstructive Pulmonary Disease". This article interprets the consensus' core points on triple therapy, analyzes its applications in diverse clinical scenarios, and provides evidence - based guidance for optimizing drug selection in Chinese COPD treatment. The goal is to improve treatment standardization and enhance patient outcomes.

在中国，慢性阻塞性肺疾病（COPD）属于常见慢性病，具有较高的发病率和死亡率，给个人健康和社会经济带来了巨大的负担。药物治疗是COPD患者管理的核心，应遵循个性化原则，其中三联疗法[吸入性糖皮质激素（ICS）、长效抗胆碱受体药物（LAMA）和长效β2受体激动剂（LABA）]备受关注。2024年意大利呼吸科专家组为规范化管理COPD患者，通过科学委员会与专家小组探讨，发布了《意大利共识：慢性阻塞性肺疾病的三联吸入治疗》。本文旨在解读该共识中有关三联疗法的核心要点，重点分析三联疗法在不同的临床情景下的适用情况，为我国临床实践中优化COPD药物选择提供参考，助力提升治疗规范化水平，减少治疗的盲目性，提高治疗效果。